Page 118 - Read Online
P. 118

Page 2 of 13                 Zahrai et al. Vessel Plus 2023;7:32  https://dx.doi.org/10.20517/2574-1209.2023.100

               catheter-based, and surgical management . When treating AMI, clinicians need to decide on methods that
                                                  [3]
               lead to the least amount of harm to each unique patient.

               AMI patients who have hemodynamic instability and/or ongoing ischemia, particularly in the presence of
                                                                                                      [4]
               an ST-elevation myocardial infarction (STEMI), may be candidates for emergency revascularization . A
               small proportion of STEMI patients may require emergency surgery due to mechanical complications of
                     [5,6]
               STEMI . However, this review will focus on the larger group requiring intervention solely for
               revascularization. In particular, the strategies that have been proposed include complete revascularization to
               address all identified coronary stenoses, or a limited revascularization of the culprit vessel responsible for
               the acute event, with consideration given to revascularize any remaining areas of potential ischemic
               jeopardy at a later time. As discussed below, this review will focus on the data supporting the timing of
               surgery in the context of an AMI, particularly after percutaneous coronary intervention (PCI). When done
               too early, coronary artery bypass grafting (CABG) has been associated with injury from reperfusion and
                                                                                      [7,8]
               systemic inflammation, poor postoperative outcomes, and an increase in mortality . On the other hand,
               delayed surgery may put the patient at risk for recurrent ischemia with the potential for myocardial loss and
               worsening left ventricular function [9,10] .


               Recent studies have provided insight into the role that patient parameters, such as AMI type, left
               ventricular, pulmonary function, and others, could inform the process of surgical revascularization
               timing [10,11] . There also appears to be a scarcity of robust clinical trials studying AMI patients who do not
               respond successfully to initial PCI or who are eligible for first-line surgical revascularization. In this review,
               we summarize the current evidence to guide decision-making for the timing of surgical revascularization for
               AMI patients.


               HISTORY OF CORONARY REVASCULARIZATION IN AMI
               Management of AMI has dramatically evolved owing to insights into the pathophysiology of coronary
               artery disease (CAD). In the mid-twentieth century, prolonged bedrest with oxygen and intravenous fluid
               therapy served as the principal treatment modality for AMI, often with fatal results . Medical therapeutic
                                                                                      [12]
               interventions have included the introduction of coronary care units with improved monitoring and
               management of arrhythmias , and the generalized use of aspirin as a potent platelet aggregation
                                         [13]
               inhibitor [14-16] .

               The recognition that AMI was a result of acute coronary thrombosis stimulated the introduction of
               thrombolysis with streptokinase as the first targeted revascularization approach in 1978, with moderate
               clinical success [12,17] . In parallel to this innovation, CABG was growing as a first-line revascularization
               therapy for CAD [18,19] . Investigations comparing surgical and non-surgical management of AMI patients
               included only nonrandomized data due to challenges with performing a clinical trial on surgical
               reperfusion [20,21] . This changed when Koshal et al. conducted the first randomized trial in 1988 to compare
                                                                                                       [22]
               surgical revascularization with conventional medical methods (excluding thrombolysis) for treating AMI .
               The authors discovered that urgent surgical reperfusion in AMI reduces early and late mortality compared
               to medical therapy.


               PCI emerged in the 1970s when Andreas Gruentzig performed the first successful PCI in a 38-year-old with
                                 [23]
                                                                                                       [24]
               stable angina in 1977 . Two years later, Geoffrey Hartzler introduced primary angioplasty to treat AMI .
               Several randomized trials and large registry studies subsequently compared primary angioplasty and
               thrombolysis, and a large meta-analysis of randomized trials including 7,739 patients confirmed the
               reduction in mortality, nonfatal reinfarction, and stroke with primary PCI, thereby justifying its wide use
               today .
                    [25]
   113   114   115   116   117   118   119   120   121   122   123